Skip to main content

Rare Diseases

Voclosporin FDA Approved for Lupus Nephritis

Jan 24, 2021

On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy. FDA approval was based on data from the pivotal AURORA

Read Article

ProDERM Study: IVIG in Dermatomyositis

Jan 13, 2021

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jan 06, 2021

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine. A novel trial of IV rilonacept, an IL-1 α and IL-1β cytokine trap, resulted in rapid resolution of recurrent pericarditis and to a

Read Article

Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)

Dec 31, 2020

JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has

Read Article

Best of 2020: The COVID-19 Global Rheumatology Registry

Dec 24, 2020

What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease

Read Article

New Lyme Disease Guidelines

Dec 10, 2020

2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The guideline

Read Article

Rheumatic Disease and COVID-19: Who Is at Risk?

MedPage Today
Dec 10, 2020

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

Read Article

ACR20 - Autoinflammatory & Still's Disease Panel

Nov 24, 2020

This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.

You can listen to this podcast on SoundCloud, iTunes, Apple Car Play

Read Article

Undifferentiated Autoinflammatory Syndrome Called VEXAS

Nov 24, 2020

Saturday's session on autoinflammatory syndromes featured Dr. Dan Kastner addressing - The Adult with Undifferentiated Autoinflammatory Disease.

Read Article

ACR20 - Day 3 Report

Nov 09, 2020

Here are my highlights from day three, Sunday, of the ACR 2020 Convergence. 

Read Article
Important thoughts- how do we actually use the biologics in practice for the rare diseases that do not have many FDA approved options? @RheumNow #ACR20 abstract 1429
alexa meara lexmeara ( View Tweet)
Nov 08, 2020

QD Clinic Podcast - 106 thru 109

Nov 05, 2020

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.

In this compilation from the past week we talk about

- HIV and arthritis

- Hyperuricemia in PsA

- An odd kind of dermatomyositis

- Running out of options in

Read Article

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on

Read Article

Abatacept in Early Systemic Sclerosis (ASSET study)

Oct 29, 2020

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).


Read Article

Immune Necrotizing Myopathy

Oct 26, 2020

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

This form of myositis has been associated with antibodies to signal recognition particle (anti-SRP) or anti-3-hydroxy-3-methylglutaryl-coA

Read Article

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Oct 23, 2020

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article

ICI Arthritis Tied to Cancer Progression

Oct 14, 2020

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.

Almost 90% of patients treated with ICI develop immune-related adverse events, which can include pulmonary,

Read Article

Biologics Beneficial in Eosinophilic Vasculitis

Oct 08, 2020

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.

Among 63 patients who were treated with rituximab (Rituxan), remission or partial responses at 1 year were observed

Read Article

2020 Nobel Prize in Medicine Goes to the Discovery of Hepatitis C

Oct 05, 2020

The Nobel Assembly at Karolinska Institutet has awarded the 2020 Nobel Prize in Physiology or Medicine jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. These three scientists made a decisive contribution to the fight against blood-borne

Read Article

RheumNow Podcast – Function Follows Form (10.2.20)

Oct 01, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.

Read Article

Slow Lung Decline Typical in Systemic Sclerosis

Sep 30, 2020

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database

Read Article

Novel Biologic Promising in Mid-Stage Scleroderma Trial

Sep 29, 2020

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.

At week 24, the least squares mean change from baseline on the modified Rodnan skin score was -4.76 for patients

Read Article

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on

Read Article

Livedo, Purpura and Coagulopathy in Severe COVID-19

Sep 23, 2020

JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.

A flurry of recent reports have described livedoid and necrotic

Read Article

Insights into Antinuclear Antibodies in Systemic Lupus Erythematosus

Sep 03, 2020

Pisetsky and Lipsky have reviewed the evolving literature on the utility of antinuclear antibodies (ANA). ANAs generated as part of an autoimmune disorder may form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction.

ANAs are directed at DNA or

Read Article